Full list of records selected for systematic review
| Clinical trial . | Author . | Year . | Title . | Journal . |
|---|---|---|---|---|
| RESPONSE | Verstovsek et al24 | 2014 | Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU) the RESPONSE trial. | Journal of Clinical Oncology |
| Vannucchi et al25 | 2014 | Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea. | Haematologica | |
| Vannucchi et al6 | 2015 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | The New England Journal of Medicine | |
| Verstovsek et al26 | 2015 | Safety of ruxolitinib in patients with polycythemia vera Results from the clinical trial program. | Haematologica | |
| Verstovsek et al7 | 2016 | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. | Haematologica | |
| Kiladjian et al27 | 2017 | Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). | Blood | |
| Alvarez-Larràn et al19 | 2018 | Comparison of ruxolitinib and real-world best available therapy in terms of overall survival and thrombosis in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. | HemaSphere | |
| Kiladjian et al28 | 2018 | Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. | Annals of Hematology | |
| Kiladjian et al20 | 2018 | Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (RUX) with best available therapy (BAT) in hydroxyurea (HU)-resistant/intolerant patients (pts) with polycythemia vera (PV). | Blood | |
| RESPONSE-2 | Passamonti et al14 | 2016 | Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: results from the phase IIIb RESPONSE-2 study. | Haematologica |
| Passamonti et al8 | 2017 | Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomized, open-label, phase 3b study. | The Lancet Oncology | |
| Passamonti et al29 | 2018 | Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 156-week follow-up from the phase 3 RESPONSE-2 study. | Blood | |
| Griesshammer et al9 | 2018 | Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. | Annals of Hematology | |
| MAJIC | Harrison et al12 | 2018 | Ruxolitinib compared with best available therapy for polycythaemia vera patients resistant or intolerant to hydroxycarbamide in MAJIC—an investigator-led randomised trial. | HemaSphere |
| Curto-Garcia et al13 | 2019 | Molecular analysis in MAJIC PV correlation with clinical endpoints. | HemaSphere | |
| RELIEF | Mesa et al10 | 2017 | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). | British Journal of Haematology |
| Clinical trial . | Author . | Year . | Title . | Journal . |
|---|---|---|---|---|
| RESPONSE | Verstovsek et al24 | 2014 | Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU) the RESPONSE trial. | Journal of Clinical Oncology |
| Vannucchi et al25 | 2014 | Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea. | Haematologica | |
| Vannucchi et al6 | 2015 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | The New England Journal of Medicine | |
| Verstovsek et al26 | 2015 | Safety of ruxolitinib in patients with polycythemia vera Results from the clinical trial program. | Haematologica | |
| Verstovsek et al7 | 2016 | Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. | Haematologica | |
| Kiladjian et al27 | 2017 | Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). | Blood | |
| Alvarez-Larràn et al19 | 2018 | Comparison of ruxolitinib and real-world best available therapy in terms of overall survival and thrombosis in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. | HemaSphere | |
| Kiladjian et al28 | 2018 | Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. | Annals of Hematology | |
| Kiladjian et al20 | 2018 | Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (RUX) with best available therapy (BAT) in hydroxyurea (HU)-resistant/intolerant patients (pts) with polycythemia vera (PV). | Blood | |
| RESPONSE-2 | Passamonti et al14 | 2016 | Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: results from the phase IIIb RESPONSE-2 study. | Haematologica |
| Passamonti et al8 | 2017 | Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomized, open-label, phase 3b study. | The Lancet Oncology | |
| Passamonti et al29 | 2018 | Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 156-week follow-up from the phase 3 RESPONSE-2 study. | Blood | |
| Griesshammer et al9 | 2018 | Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. | Annals of Hematology | |
| MAJIC | Harrison et al12 | 2018 | Ruxolitinib compared with best available therapy for polycythaemia vera patients resistant or intolerant to hydroxycarbamide in MAJIC—an investigator-led randomised trial. | HemaSphere |
| Curto-Garcia et al13 | 2019 | Molecular analysis in MAJIC PV correlation with clinical endpoints. | HemaSphere | |
| RELIEF | Mesa et al10 | 2017 | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). | British Journal of Haematology |